Janssen Therapeutics' OLYSIO Inhibitor Receives FDA Approval for Hepatitis C Treatments

Janssen Therapeutics, a division of Janssen Products, announced that the U.S. Food and Drug Administration approved OLYSIO (simeprevir), an NS3/4A protease inhibitor.

The inhibitor has been approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen. OLYSIO works by blocking the viral protease enzyme that enables the hepatitis C virus to replicate in host cells.

More Articles on Supply Chain:

5 Ways Materials Management Information Systems Can Improve Surgery Center Supply Chain
Mazor Robotics' Sells Renaissance Spine System to Lawnwood Regional Medical Center
Alphatec Spine Posts $14.5M Q3 Loss After PurGen Device Discontinuation

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars